PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION
1.1 Product Outline
1.1.1 Personalized Medicine’s Influence on Large Scale Studies
1.1.2 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine
1.1.3 Ramifications of Personalized Medicine for Healthcare Systems
1.1.3.1 Pharmaceutical Industry
1.1.3.2 Diagnostics Industry
1.1.3.3 Insurers
1.1.3.4 Physicians
1.1.3.5 Government Agencies
1.1.3.6 Patients
1.1.4 Analysis of Personalized Medicine by Segment
1.1.4.1 Targeted Biologics
1.1.4.1.1 Overview
1.1.4.1.2 Targeted Biologics for Breast Cancer: An Illustration
1.1.4.1.2.1 Targeted Biologic Therapy for Breast Cancer
1.1.4.2 Proteomics & Genomics
1.1.4.2.1 Proteomics
1.1.4.2.1.1 A Complex Problem
1.1.4.2.1.2 Post-Translational Modifications
1.1.4.2.1.3 Phosphorylation
1.1.4.2.1.4 Ubiquitination
1.1.4.2.1.5 Other Modifications
1.1.4.2.1.6 Inadequacies in Proteomics Studies
1.1.4.2.1.7 Proteomics in Practical Applications
1.1.4.2.2 Genomics
1.1.4.2.2.1 Pharmacogenomics
1.1.4.3 Genetically Modified (GM) Products
1.1.4.3.1 The Genetic Engineering Process
1.1.4.3.1.1 Applications of Genetic Engineering
1.1.4.4 Wellness & Disease Management
1.1.4.4.1 Wellness Defined
1.1.4.4.1.1 The Ten Dimensions of Wellness
1.1.4.4.2 Disease Management Defined
1.1.4.5 Molecular Diagnostic Technologies
1.1.4.5.1 DNA Sequencing
1.1.4.5.2 Biochips and Microarrays
1.1.4.5.2.1 Personalized Medicine Development Using DNA Biochip Technology
1.1.4.5.2.2 Protein Biochips’ Role in Personalized Medicine
1.1.4.5.3 Cytogenetics
1.1.4.5.3.1 Personalized Medicine Based on Molecular Cytogenetics
1.1.4.5.3.2 Personalized Medicine Based on Cytomics
1.1.4.5.4 Single Nucleotide Polymorphism (SNP) Genotyping
1.1.4.5.4.1 Technologies for SNP Analysis
1.1.4.5.4.2 Applications of SNPs Pertinent to Personalized Medicine
1.1.4.5.5 Haplotyping
1.1.4.5.5.1 HapMap Project
1.1.4.5.5.2 HapMap for Predicting Drug Response
1.1.4.5.6 Application of Proteomics in Molecular Diagnosis
1.1.4.5.6.1 Proteomic and Genomic Approaches in Personalized Medicine Compared
1.1.4.5.7 Gene Expression Profiling
1.1.4.5.8 Personalized Medicine and Molecular Imaging
1.1.4.5.9 Diagnostics Based On Glycomics
1.1.4.5.10 Combining Diagnostics and Therapeutics
1.1.4.5.11 Point-Of-Care (POC) Diagnosis
1.1.4.5.11.1 Point-of-Care Diagnosis of Infections
1.1.4.5.11.2 Positives and Negatives of Point-of-Care Diagnosis
1.1.4.5.12 Genetic Testing For Disease Predisposition
1.1.5 Analysis of Personalized Medicine by Technology
1.1.5.1 Pharmacogenomics
1.1.5.1.1 Drug Metabolism
1.1.5.1.2 Applications
1.1.5.2 Point-of-Care Testing
1.1.5.2.1 Tests that are Most Apt for Specific Scenarios
1.1.5.2.1.1 Primary Care
1.1.5.2.1.2 Emergency Room
1.1.5.2.1.3 Intensive Care
1.1.5.2.2 Advantages
1.1.5.3 Stem Cell Therapy
1.1.5.3.1 Treatment with Stem Cells
1.1.5.3.2 Current Therapies
1.1.5.3.3 Future Treatments
1.1.5.4 Pharmacoproteomics
1.1.5.5 Pharmacogenetics
1.1.5.5.1 Prediction of Drug-Drug Interactions
1.1.5.5.2 Integration of Pharmacogenetics with the Healthcare System
1.1.5.5.3 Pharmacogenetic Tests
1.1.5.5.4 Currently Used Tests
1.1.5.6 Other Personalized Medicine Technologies
1.1.5.6.1 Biochips
1.1.5.6.1.1 Fabrication of Microarrays
1.1.5.6.1.2 Protein Biochip Array and Other Microarray Technologies
1.1.5.6.1.3 Biochips Applications: Ranging from Diagnostics to Personalized Medicine
1.1.5.6.2 Genetic Screening
1.1.5.6.2.1 Basic Screening
1.1.5.6.2.2 Screening Variations
1.1.5.6.2.3 Genetic Screening: Ethical Issues and Concerns
1.1.5.6.3 Metabolomics
1.1.5.6.4 Molecular Diagnostics
1.1.5.6.4.1 Molecular Diagnostics for Personalized Medicine
1.1.5.6.5 Pharmacodynamics
1.1.5.6.6 Pharmacokinetics
1.1.5.6.7 SNP Genotyping
1.1.5.6.7.1 Core Labs
1.1.5.6.7.2 Hybridization-Based Methods
1.1.5.6.7.3 Enzyme-Based Methods
1.1.5.6.7.4 Other Post-Amplification Methods Based on Physical Properties of DNA
1.1.6 The Rationale Behind Personalized Medicine: "One Size no Longer Fits All"
1.1.7 The Human Genome: What is It?

2. KEY MARKET TRENDS
Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs
Personalized Medicine for Heart Patients Promised by University of Florida Academic Health Center
Personalized Medicine Integrated with Biosensors
Decade-Long Penn Medicine Study of HIV Patients Demonstrates Safety of Genetically Modified T Cell Therapy
Managing Infectious Diseases Using Point-of-Care Personalized Medicine Molecular Diagnostic Technologies
Introduction
Personalized Medicine and Infectious Diseases: An Unlikely Combination?
Universities to be Commended for Bringing Personalized Medicine to Patient Care
Nuclear Imaging Market to be Boosted through a Trend towards Personalized Medicine
Personalized Medicine for Lung Cancer Makes Progress
Micro RNA Denotes Response to Chemoprevention
Shorter Survival Predicted from RRM
Differentiating Tumor Types through Epigenetic Clues
Pharmaceutical and Diagnostic Company Business Models being Challenged by Personalized Medicine
Personalized Medicine and Pharmacogenomics: Single Nucleotide Polymorphisms’ (SNPs) Role in Drug Therapy
Personalization of Medicine and the Role of SNPs
The Arrival of Pharmacogenetics and Illustrations of SNPs in Personalized Medicine
Personalized Medicine’s Drawbacks in the Context of Genetic Discrimination
Personalized Medicine’s Promise of Offering the Future Now
The Course of Advancements in Cancers
Live Healthy to Make a Difference
Personalized Medicine in Cancer Hits a Roadblock
Implications of Personalized Medicine for Pharmaceutical Manufacturers and Drug Development
Implications of Personalized Medicine
What Should Drug Developers Do
Is Drug Safety Capable of Being Improved through Personalized Medicine?
Personalized Medicine: A SWOT Analysis for Pharmacists
–Strengths
–Weaknesses
–Opportunities
–Threats
Genetic Testing for Identifying and Treating Specific Disorders
The Scientific and Commercial Facets of Personalized Medicine
Prevention and Treatment of Diabetes with Personalized Medicine
Medical Informatics and Personalized Medicine
Personalized Medicine for Treating Asthma
Personalized Medicine and Systems Engineering
The Evolving Role of CROs in Personalized Medicine
Personalized Medicine Being Guided by Stem Cell Therapies
Device Manufacturers Offered Better Prospects from the Trend Towards Personalized Medicine

3. KEY GLOBAL PLAYERS

4. KEY BUSINESS TRENDS
Lilly Partners with PrimeraDX for Novel Personalized Therapeutics
Sanofi Joins with Joslin Diabetes Center to Develop New Drugs
New Personalized Medicine Center to be Opened by PerkinElmer
Roche Signs Strategic Pact with Med Fusion
Agendia Introduces a New 18-Gene Expression Signature
Affymetrix Enters Research Collaboration with MGH
Affymetrix Signs Research Contract with Leica
Millennium Labs Launches Innovative Pharmacogenetic Test
Genedata Expressionist Opted for by Takeda
Boehringer Ingelheim and Healthrageous in an Agreement
Merck KGaA and MDxHealth Form Collaboration
FDA Approves Colorectal Cancer Companion Diagnostic from Qiagen
KineMed Collaborates with GSK for Biomarker Discovery
bioTheranostics Expands PRÉCIS Biomarker Profiles
Quest Introduces New Molecular Test Panel
Biocartis Collaborates with Philips and Wellcome Trust
Agreement Signed between Immunexpress, Debiopharm, and Biocartis
Lab21 Sings Pact with Major Pharma Company to Develop Companion Diagnostic Assay
Clarient Acquires IP Rights for Developing ALK Biomarker Genetic Tests from Insight Genetics
Exosome Signs and Life Technologies Sign an Agreement
NextGen Commercializes Assay for New Diagnostics Biomarkers in Brain Disorders
Sanofi Collaborates with Joslin Diabetes Center
Perjeta™ (Pertuzumab) for People with HER2-Positive Metastatic Breast Cancer Granted FDA Approval
Software Re-enlisted by Roche for Personalized Medicine Research
Teva All Set to Enter Personalized Medicine Field
Personalized Medicine Test for ADHD Launched by AssureRx Health
XALKORI® Launched in Canada by Pfizer
Abbott Acquires License for Novel Biomarkers from Stanford
GE Bags SeqWright
PerkinElmer Unveils HER2Sense for Breast Cancer Research
Celgene Files FDA Application for Multiple Myeloma Drug
Takeda and Metabolon in a Partnership
Biomed Analytics Platform Tested by IBM in Association with Italian Institute
Abbott Joins Hands with Merck to Develop Companion Diagnostic Test
Chronix Biomedical Inaugurates State-of-the-Art Mass Sequencing Laboratory for Personal Biomarkers
Personalized Medicine Offered by IBM Genomic Analytics Platform
Clinical Genomics Centre Launched in USA by Lab21 and ITOR
GlaxoSmithKline and Epistem in an Agreement
Online Personalized Medicine Portal Launched by Cepmed
Dako Partners with Amgen to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Personalized Medicine Partnership of Florida is to be Created
China’s SFDA Approves First Microarray Instrument GCS 3000Dx v.2
Health Canada Approves First and Only Personalized Treatment for Deadliest Form of Skin Cancer
New Personalized Medicine Institute Launched by Moffitt Cancer Centre
Roche Bags EU Approval for Zelboraf
Amgen and Dako in an Alliance for Developing New Diagnostic Test for Cancer Therapy
Siemens Enters Personalized Medicine Field
Ventana Medical and Bayer Joins Forces to Develop Companion Diagnostic Test
AssureRx Launches GeneSightRx 1.8
bioTheranostics Unveils Precision Medicine Biomarkers
Identification of DNA Variants for Personalized Medicine Research by Ingenuity
Genzyme and Veracyte in an Agreement
OvaGene Joins Forces with Moffitt Cancer Center
GlaxoSmithKline and Abbott in Agreement to Expand Personalized Medicine for Cancer Diagnostic
Siemens and Illumina in a Partnership
Pfizer’s Xalkori and Abbott Demonstrate a Bright Scope in Personalized Medicine, Companion Diagnostics
GNS Healthcare Collaborates with Bristol-Myers Squibb
Genetically Modified Human Cell Lines for Breast Cancer Research from Sigma® Life Science
Coriell Partners with IBM
QIAGEN Agrees to Acquire 61% Stake in Ipsogen
Joint Development of Biomarkers in Oncology by Roche and Evotec
Innovative COX-2 Probe Launched by Caliper Life Sciences
Caliper and Catholic Health Initiatives form Oncology Research Collaboration
Novel Patient-Specific Drug Targets Identified by GNS Healthcare and Biogen
Daiichi Sankyo Takes Over Plexxikon
Collaboration between Ipsen SA and BioMerieux SA in Personalized Medicine
AstraZeneca and HealthCore Form Collaboration
Minority Stake in Alacris Theranostics acquired by QIAGEN
GenomeQuest and Ingenuity Systems Form Partnership
Veridex and Massachusetts General Hospital Form Collaboration
Development of Personalized Medicine Further Accelerated with the Partnership between Dako and Quintiles
First Pharmacogenomics Test Launched by Luminex Corp. for Personalized Medicine
Integration of Software between Ingenuity Systems and TransMed to Support Personalized Medicine Research
Advancement of Personalized Medicine with the Launch of New Multiplex Tissue Biomarker Technology
Personalized Medicine Brought to Market by Iris Biotechnologies

5. GLOBAL MARKET OVERVIEW
5.1 Market Overview by Product Type
5.2 Market Overview by Technology
5.3 Personalized Medicine Product Type Overview by Global Region
5.3.1 Targeted Biologics
5.3.2 Proteomics & Genomics
5.3.3 Genetically Modified (GM) Products
5.3.4 Wellness & Disease Management
5.3.5 Other Molecular Diagnostic Products
5.3.6 Self/Other Diagnostics
5.4 Personalized Medicine Technology Overview by Global Region
5.4.1 Pharmacogenomics
5.4.2 Point-of-Care Testing
5.4.3 Stem Cell Therapy
5.4.4 Pharmacoproteomics
5.4.5 Pharmacogenetics
5.4.6 Other Personalized Medicine Technologies

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES
1.1 Market Overview by Product Type
1.2 Market Overview by Technology
1.3 Major Market Players
Abbott Laboratories, Inc.
Abbott Molecular Inc
Affymetrix, Inc.
Agilent Technologies, Inc.
Amgen, Inc.
Asuragen, Inc.
Baxter International Inc.
Beckman Coulter Genomics Inc.
Beckman Coulter, Inc.
BG Medicine, Inc.
Biogen Idec
Bristol-Myers Squibb Company
Caliper Life Sciences, Inc.
Celera Corporation
Celgene Corporation
Celldex Therapeutics
Cepheid
DNA Direct, Inc.
Eli Lilly and Company
Exact Sciences Corp.
Exagen Diagnostics, Inc.
Gene Logic
Genelex Corporation
Genentech, Inc.
Genomic Health Inc
Gen-Probe Incorporated
Genzyme Corporation
HistoRx, Inc.
Hologic Inc
Illumina, Inc.
Ingenuity Systems, Inc.
Johnson & Johnson
Laboratory Corporation of America (LABCORP)
Life Technologies Corporation
Luminex Corporation
Millennium Laboratories
Myriad Genetics, Inc.
PerkinElmer, Inc.
Pfizer Inc
Promega Corporation
Roche Diagnostics Corporation
Siemens Healthcare Diagnostics Inc.
Sigma-Aldrich Corporation
Thermo Fisher Scientific Inc
Ventana Medical Systems, Inc.

2. EUROPE
2.1 Market Overview by Product Type
2.2 Market Overview by Technology
2.3 Major Market Players
Agendia B.V. (The Netherlands)
AstraZeneca PLC (United Kingdom)
Bayer AG (Germany)
Bayer Healthcare AG (Germany)
Bayer Healthcare Pharmaceuticals (Germany)
Biocartis NV (Belgium)
Biocartis SA (Switzerland)
bioMérieux SA (France)
Boehringer Ingelheim GmbH (Germany)
Cytolon AG (Germany)
Dako A/S (Denmark)
Decode Genetics (Iceland)
Epistem Holdings PLC (United Kingdom)
Evotec AG (Germany)
GE Healthcare Ltd. (United Kingdom)
GlaxoSmithKline, PLC (United Kingdom)
Merck KGaA (Germany)
Novartis AG (Switzerland)
Qiagen N.V. (The Netherlands)
Roche Holding Ltd. (Switzerland)
Sanofi (France)
Siemens AG (Germany)
Siemens Healthcare (Germany)
The European Personalised Medicine Association (EPEMED) (Luxembourg)

3. REST OF WORLD
3.1 Market Overview by Product Type
3.2 Market Overview by Technology
3.3 Major Market Players
Astellas Pharma Inc. (Japan)
Cepmed (Canada)
Daiichi Sankyo Company Limited (Japan)
DNA Genotek Inc. (Canada)
Mitsubishi Tanabe Pharma Corporation (Japan)
Rosetta Genomics Ltd. (Israel)
Teva Pharmaceutical Industries Ltd. (Israel)
Takeda Pharmaceutical Company Limited (Japan)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA
1.1 Canada
1.2 United States

2. EUROPE
2.1 Austria
2.2 Belgium
2.3 Denmark
2.4 France
2.5 Germany
2.6 Iceland
2.7 Ireland
2.8 Italy
2.9 Luxembourg
2.10 Spain
2.11 Switzerland
2.12 The Netherlands
2.13 United Kingdom

3. ASIA-PACIFIC
3.1 Australia
3.2 China
3.3 Hong Kong
3.4 Japan
3.5 New Zealand
3.6 South Korea
3.7 Taiwan

4. REST OF WORLD
4.1 Israel

5. RESEARCH & EDUCATIONAL INSTITUTIONS

PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE
Chart 1: Global Personalized Medicine Market Analysis (2008-2018) in USD Million
Chart 2: Global Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
Chart 3: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
Chart 4: Global Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
Chart 5: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies
Chart 6: Global Market Analysis of Targeted Biologics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 7: Glance at 2008, 2013 and 2018 Global Market Share (%) of Targeted Biologics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 8: Global Market Analysis of Proteomics & Genomics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 9: Glance at 2008, 2013 and 2018 Global Market Share (%) of Proteomics & Genomics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 10: Global Market Analysis of Genetically Modified (GM) Products in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 11: Glance at 2008, 2013 and 2018 Global Market Share (%) of Genetically Modified (GM) Products in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 12: Global Market Analysis of Wellness & Disease Management in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 13: Glance at 2008, 2013 and 2018 Global Market Share (%) of Wellness & Disease Management in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 14: Global Market Analysis of Other Molecular Diagnostics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 15: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Molecular Diagnostics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 16: Global Market Analysis of Self/Other Diagnostics in Personalized Medicine (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 17: Glance at 2008, 2013 and 2018 Global Market Share (%) of Self/Other Diagnostics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 18: Global Market Analysis of Pharmacogenomics in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
Chart 19: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenomics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 20: Global Market Analysis of Point-of-Care Testing in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
Chart 21: Glance at 2008, 2013 and 2018 Global Market Share (%) of Point-of-Care Testing in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 22: Global Market Analysis of Stem Cell Therapy in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
Chart 23: Glance at 2008, 2013 and 2018 Global Market Share (%) of Stem Cell Therapy in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 24: Global Market Analysis of Pharmacoproteomics in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
Chart 25: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacoproteomics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 26: Global Market Analysis of Pharmacogenetics in Personalized Medicine (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
Chart 27: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenetics in Personalized Medicine by Geographic Region - United States, Europe and Rest of World
Chart 28: Global Market Analysis of Other Personalized Medicine Technologies (2008-2018) Geographic Region - United States, Europe and Rest of World in USD Million
Chart 29: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Personalized Medicine Technologies by Geographic Region - United States, Europe and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE
Chart 30: Global Personalized Medicine Market Analysis (2008-2018) by Geographic Region - United States, Europe and Rest of World in USD Million
Chart 31: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Geographic Region - United States, Europe and Rest of World

REGIONAL MARKET OVERVIEW

THE UNITED STATES
Chart 32: United States Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
Chart 33: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
Chart 34: United States Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
Chart 35: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

EUROPE
Chart 36: European Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
Chart 37: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
Chart 38: European Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
Chart 39: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

REST OF WORLD
Chart 40: Rest of World Personalized Medicine Market Analysis (2008-2018) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million
Chart 41: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Product Type - Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics
Chart 42: Rest of World Personalized Medicine Market Analysis (2008-2018) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million
Chart 43: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Technology - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

MAJOR GLOBAL MARKET PLAYERS:

Abbott Laboratories, Inc.
Affymetrix, Inc.
Agendia B.V.
Agilent Technologies, Inc.
Amgen, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Baxter International Inc.
Bayer AG
Bayer Healthcare AG
Beckman Coulter, Inc.
BG Medicine, Inc.
Biocartis NV
Biocartis SA
Biogen Idec
bioMerieux SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Caliper Life Sciences, Inc.
Celera Corporation
Celgene Corporation
Cytolon AG
Daiichi Sankyo Company Limited
Dako A/S
Decode Genetics
Eli Lilly and Company
Evotec AG
GE Healthcare Ltd.
Gene Logic
Genelex Corporation
Genentech, Inc.
Gen-Probe Incorporated
Genzyme Corporation
GlaxoSmithKline, PLC
HistoRx, Inc.
Ingenuity Systems, Inc.
Johnson & Johnson
Laboratory Corporation of America
Life Technologies Corporation
Merck KGaA
Millennium Laboratories
Mitsubishi Tanabe Pharma Corporation
Myriad Genetics, Inc.
Novartis AG
PerkinElmer, Inc.
Pfizer Inc
Roche Diagnostics Corporation
Roche Holding Ltd.
Sanofi
Siemens AG
Siemens Healthcare Diagnostics Inc.
Sigma-Aldrich Corporation
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
The European Personalized Medicine Association (EPEMED)
Thermo Fisher Scientific Inc